Research Alert
Newswise — Cheng et al. delineate a comprehensive m6A landscape during acute myeloid leukemia (AML) development and identify PRMT6, regulated by IGF2BP2, acting as a key for leukemia stem cell maintenance by restraining MFSD2A expression and docosahexaenoic acid levels. These findings provide the rationale for targeting PRMT6-MFSD2A signaling axis in AML therapy.
MEDIA CONTACT
Register for reporter access to contact detailsCITATIONS
DOI link; Publisher Website; Download PDF